Omics-Informed TMS Mechanisms in TRD: Implications for Psychedelic Research

Transcranial Magnetic Stimulation in TRD: Omics Evidence at a Glance

Transcranial magnetic stimulation (TMS) is a non-invasive neuromodulation technique with established efficacy for treatment-resistant depression (TRD), a severe form of major depressive disorder (MDD) unresponsive to standard therapies. According to a 2026 narrative review (OpenAlex W7223039237), TMS induces biological changes across transcriptomic, epigenomic, proteomic, metabolomic, and connectomic levels, though the precise mechanisms underlying clinical response remain incompletely understood. The review synthesizes both published studies and secondary analyses of public omics datasets, providing a comprehensive update on the molecular and circuit-level effects of TMS in TRD.

Mechanistic Insights: Neuroplasticity, Epigenetics, and Circuit Remodeling

Current omics research indicates that TMS modulates gene expression and neural circuits implicated in depression. Transcriptomic and spatial transcriptomic studies reveal that TMS alters cell type- and region-specific transcriptional programs related to synaptic plasticity and neuronal development. For example, upregulation of genes associated with dendritic growth and synaptic signaling has been observed in prefrontal cortex regions targeted by TMS. Epigenetic evidence, including changes in DNA methylation and histone lactylation, suggests that TMS may induce lasting modifications in gene regulation, potentially supporting sustained antidepressant effects.

Proteomic and metabolomic analyses further demonstrate shifts in synaptic proteins, neurotransmitter systems, lipid metabolism, and peripheral metabolites following TMS. Notably, some studies document increased levels of brain-derived neurotrophic factor (BDNF), a key mediator of neuroplasticity, echoing findings from psychedelic trials. Connectomic studies using functional and structural imaging show that TMS can reconfigure prefrontal and large-scale brain networks, correlating with clinical response in TRD. However, the review underscores that direct causal links between molecular changes and circuit remodeling remain largely unproven, highlighting a critical knowledge gap for both TMS and psychedelic interventions.

Policy and Research Implications: Biomarkers and Trial Design

The multi-omics approach outlined in the review has significant implications for the future of both TMS and psychedelic research in TRD. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) increasingly expect mechanistic and biomarker data to support novel neuropsychiatric interventions. The review calls for longitudinal, multi-omics studies in real-world TRD populations, which can help identify predictive biomarkers, clarify mechanisms of action, and enable individualized treatment protocols.

This approach is already influencing psychedelic clinical trials, where multi-omics sampling (e.g., blood, cerebrospinal fluid, neuroimaging) is being integrated into phase II and III protocols to track biological signatures of response. A non-obvious implication is that omics-informed stratification may soon become a requirement for regulatory approval of both TMS and psychedelic-based therapies, especially for subgroups with high relapse risk or atypical depression phenotypes. This could shift trial design toward adaptive, biomarker-guided methodologies, increasing complexity but potentially improving efficacy and safety outcomes.

Risks, Unknowns, and the Limits of Current Evidence

Despite promising findings, the review highlights substantial limitations and risks. The majority of omics studies in TMS are cross-sectional, involve small cohorts, and lack standardized protocols, limiting reproducibility and generalizability. There is also a risk of overinterpreting correlational data, as direct causal relationships between molecular changes and clinical improvement are not yet established. Furthermore, the heterogeneity of TRD—spanning genetic, metabolic, and environmental factors—complicates biomarker discovery and individualized treatment strategies.

For psychedelic research, these limitations are particularly salient. The field faces similar challenges in linking acute molecular and circuit-level changes to long-term remission in depression. Without robust longitudinal data and causal inference, both TMS and psychedelic interventions risk being adopted based on incomplete mechanistic understanding, potentially exposing patients to unknown risks or suboptimal outcomes.

Looking Ahead: Toward Integrated, Mechanism-Based Therapies

Future research in TRD will likely emphasize longitudinal, multi-omics studies that integrate molecular, cellular, and circuit-level data with clinical outcomes. For both TMS and psychedelic therapies, this approach could enable the identification of reliable biomarkers for response, inform patient selection, and guide adaptive treatment protocols. Importantly, the review suggests that cross-disciplinary collaboration—combining expertise in neurobiology, psychiatry, omics, and data science—will be essential to overcome current methodological and interpretive challenges.

As regulatory expectations evolve, the integration of omics data into clinical trial design and approval processes may become standard practice for neuromodulation and psychedelic therapies alike. This shift could accelerate the development of more precise, mechanism-based treatments for TRD, but will require sustained investment in high-quality, longitudinal research and transparent data sharing across the field.

How we research: This article was written and reviewed by Dr. Alex R. Mendel, PhD (Neuroscience, Stanford), on 2026-10-22. Primary sources include the cited OpenAlex review and referenced omics studies. All regulatory context is based on FDA and EMA documentation as of October 2026.